Imaging-based Diagnosis of Diffuse Coronary Artery Disease and Quantification of Cardiac Remodeling in Obesity

June 24, 2020 updated by: National Heart Centre Singapore

The study aims to:

  1. Characterize coronary artery disease (CAD) using CT Angiography (CTA) and scaling power law in 100 patients with obesity
  2. Characterize cardiac remodeling using curvedness-based MRI in 100 patients with obesity
  3. Compare the differences of cardiac and vascular remodeling in patients with metabolic syndrome and those without

Study Overview

Status

Completed

Conditions

Detailed Description

Background and Objectives:

Obesity is a common [affecting about 33% in the general adult population in US] metabolic disorder and it is increasing in prevalence in Singapore (about 10% of general adult population). As obesity is associated with cardiovascular disease (i.e., diffused coronary artery disease, DCAD) and leads to heart remodeling and heart failure, timely and accurate diagnosis of diffused coronary artery disease and its related cardiac remodeling in obesity is clinically urgently needed and this study aims to:

  1. Characterize coronary artery disease (CAD) using CTA and scaling power law in 100 patients with obesity
  2. Characterize cardiac remodeling using curvedness-based MRI in 100 patients with obesity
  3. Compare the differences of cardiac and vascular remodeling in patients with metabolic syndrome and those without

Methodologies: 100 patients with obesity will be recruited for this study. All recruited patients will undergo fasting blood test for diagnosing metabolic syndrome. After that, they will undergo CTA and MRI within 1-2 weeks in-between. Patients' CTA images will be segmented and transformed to build 3D coronary artery models. The application of novel scaling power laws on these models will be used to diagnose diffuse CAD. Based on patients MRI images, the cardiac remodeling will be assessed with a novel curvedness-based imaging analysis method. The differences of cardiac and vascular remodeling in patients with metabolic syndrome and those without will be compared and analyzed.

In addition, subjects shall undergo ultrasound examination of the heart (echocardiogram), carotids and forearm arteries. Doppler and tissue-Doppler echocardiography constitutes the gold standard for cardiac diastolic function assessment. The findings shall be correlated with diastolic cine MRI findings. Carotid and forearm artery ultrasound allows investigation of vessel distensibility, carotid intimal thickness, pulse wave velocity, central arterial blood pressure estimation as well as endothelial function (via flow-mediated dilation). Perturbations of these parameters may be correlated with functional abnormalities on cardiac MRI and coronary disease on CT.

Subjects shall undergo fasting blood tests for metabolic profiling. The tests include blood levels of creatinine, electrolytes, insulin, glycated haemoglobin, fasting lipids, fasting sugar and postprandial sugar (75 g standard oral glucose load). Additionally blood samples shall be stored for potential future studies.

Clinical Significance: If success, this study in obesity should advance understanding of obesity-related CAD and cardiac and vessel remodeling, and further translate into improved diagnosis and treatment in obese patients.

Clinical Significance: If success, this study in obesity should advance understanding of obesity-related CAD and cardiac remodeling, and further translate into improved diagnosis and treatment in obese patients.

Study Type

Observational

Enrollment (Actual)

52

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Singapore, Singapore, 169609
        • National Heart Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Total recruitment number: 100 Participants' age limit of 21 to 80.

Description

Inclusion Criteria:

  1. Aged 21-80.
  2. with obesity BMI ≥27 .
  3. Written informed consent obtained

Exclusion Criteria:

  1. Individuals unable to provide informed consent.
  2. Non-cardiac illness with life expectancy <2 years.
  3. Pregnant state.
  4. Allergy to iodinated contrast.
  5. Significant arrhythmia; heart rate ≥ 100 beats/min; systolic blood pressure ≤90 mmHg.
  6. Renal dysfunction (Glomerular filtration rate (GFR) <45 mL/min/1.73m2).
  7. Contraindication to beta blockers or nitroglycerin.
  8. Canadian Cardiovascular Society class IV angina.
  9. with Cardiac pacemaker
  10. with brain aneurysm or clips
  11. with Electronic implants or prosthesis
  12. with Eye metal foreign body injury
  13. Severe claustrophobia
  14. Thyroid dysfunction

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diagnosis of diffuse coronary artery disease using imaging techniques and quantification of cardiac remodeling in obesity
Time Frame: 36 months
Imaging-based techniques used are MRI, CTA and Echocardiogram. Fasting blood tests will be carried out to determine metabolic syndrome. Cardiac and vascular remodeling in participants with metabolic syndrome and those without will be compared and analyzed.
36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: RU SAN TAN, National Heart Centre

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2014

Primary Completion (Actual)

March 31, 2017

Study Completion (Actual)

October 1, 2019

Study Registration Dates

First Submitted

May 31, 2016

First Submitted That Met QC Criteria

February 6, 2017

First Posted (Estimate)

February 8, 2017

Study Record Updates

Last Update Posted (Actual)

June 25, 2020

Last Update Submitted That Met QC Criteria

June 24, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Subscribe